Well we have a new FDA now, hopefully, but it’s going to take
companies and scientists going to the FDA and to Congress to say “look the patient
population is aging and currently we have a bottleneck, we can’t get these medicines
through” and try to work out some new policy. Hopefully, the FDA will be a little more
progressive about looking at endpoints. They are very, very conservative about what
endpoints they will accept